Tyrosine Kinase Inhibitors (TKIs) for the Treatment of Concurrent Colorectal and Renal Cell Carcinomas

Apart from representing relatively rare incidents, multiple primary malignancies pose, also, a therapeutic challenge. Treatment with anti-angiogenetic tyrosine kinase inhibitors have been proven to be effective in a variety of malignancies, including advanced renal cell and colorectal cancers. Herein, we report an interesting case of a 69-years-old male with renal cell carcinoma with pulmonary metastases and a synchronous localized colon cancer, who achieved significant responses to both cancers after first-line treatment with pazopanib and second-line treatment with axitinib. In the era of targeted therapies, angiogenesis inhibition may serve as an efficacious and well-tolerated therapeutic option in patients with coexisting colorectal and kidney tumors.